PNC-27 is a peptide derived from the HDM-2 (human double minute 2) binding domain of p53 combined with a transmembrane-penetrating sequence. Unlike conventional p53 pathway drugs that work intracellularly by reactivating p53 transcription, PNC-27 acts at the cell membrane: it binds HDM-2 expressed aberrantly on the outer membrane of cancer cells, triggers peptide-lipid insertion, and forms pores that lyse the cell. The selectivity arises because HDM-2 is present on cancer cell surfaces (where p53 is overexpressed and sequesters HDM-2) but not on normal cell membranes. Human Phase 0 data (Bowne et al. 2017) demonstrated PNC-27 selectively lysed tumour cells in ascites fluid from pancreatic cancer patients — the only clinical-grade data for a membranolytic anticancer peptide.
PNC-27 mechanism is entirely distinct from checkpoint inhibitors, cytotoxics, or kinase inhibitors:
HDM-2 surface expression: In cancer cells, overexpressed p53 is sequestered by HDM-2 (MDM-2 in mice) — a fraction of HDM-2 traffics to the outer membrane. Normal cells do not display surface HDM-2.
PNC-27 binding: p53 HDM-2 binding domain in PNC-27 recognises and binds surface HDM-2 → peptide anchors to cancer cell surface
Necrosis (not apoptosis): Pore formation drives osmotic lysis → necrotic death within minutes. Independent of p53 status, caspases, or BCL-2 — not subject to apoptosis resistance mechanisms
Why membranolytic mechanism matters for apoptosis-resistant cancers
Most cancer cell resistance mechanisms target apoptotic pathways — BCL-2 overexpression, caspase inactivation, p53 mutation. PNC-27 kills via membrane disruption (necrosis) — completely independent of these resistance pathways. If a cancer cell displays surface HDM-2, PNC-27 will lyse it regardless of p53 mutation status, BCL-2 levels, or chemotherapy resistance. This makes PNC-27 the research tool for studying apoptosis-independent cancer cell killing.
Key Research Studies & Clinical Data
Key PNC-27 research
Study
Model
Key result
Bowne et al. 2008 (Ann Surg Oncol)
Pancreatic, breast, melanoma cell lines in vitro
PNC-27 lysed cancer cells selectively; normal cells unaffected at equivalent doses
Bowne et al. 2017 (Cancer Biol Ther)
Phase 0 human — pancreatic cancer ascites fluid ex vivo
PNC-27 selectively lysed tumour cells in patient ascites — first human evidence for membranolytic selectivity
Sarafraz-Yazdi et al. 2010
Mechanism: HDM-2 surface expression
Confirmed surface HDM-2 as cancer-selective receptor; blocking with anti-HDM-2 antibody abolished PNC-27 effect
Research Protocols — PNC-27
Protocol 1: Cancer cell selectivity panel
PNC-27 1–50 µM in 6–8 cancer cell lines (MiaPaCa-2, MCF-7, A375 melanoma, PANC-1) vs normal counterpart cells (human dermal fibroblasts, HUVEC, PBMCs). Viability (MTT, 24hr), membrane integrity (LDH release, trypan blue), caspase activation (fluorometric) — establish selectivity index and confirm necrotic mechanism.
Protocol 2: HDM-2 surface expression
Flow cytometry (non-permeabilised cells): anti-HDM-2 antibody in cancer vs normal cell panel. Confirm surface HDM-2 as selectivity determinant. Correlate HDM-2 surface expression with PNC-27 IC50.
Protocol 3: Mechanism of death
PNC-27 10 µM in MiaPaCa-2. Time course (5/15/30/60 min): LDH, PI uptake (necrosis), Annexin V (early apoptosis), caspase-3 (late apoptosis), ATP depletion (luminescence). Confirm necrosis-first kinetics.
Protocol 4: In vivo tumour model
PANC-1 xenograft in nude mice (5×10⁶ cells SC flank). PNC-27 5–15 mg/kg IP daily × 14 days vs vehicle. Tumour volume, body weight, organ histology, survival curve. QSC-grade vs literature dose validation.
❓
Frequently Asked Questions
What is PNC-27?
PNC-27 is a p53-derived anticancer peptide that binds HDM-2 (MDM-2) expressed aberrantly on the surface of cancer cells and forms membrane pores — causing rapid necrotic cell death. It is selective for cancer cells because normal cells do not express surface HDM-2.
How does PNC-27 kill cancer cells?
PNC-27 uses a two-step mechanism: (1) its p53 HDM-2-binding domain recognises surface HDM-2 on cancer cells, anchoring the peptide to the membrane; (2) its transmembrane domain inserts into the lipid bilayer and forms lytic pores — causing rapid osmotic necrosis. This is independent of p53, caspases, or BCL-2.
Why is PNC-27 selective for cancer cells?
Surface HDM-2 expression is the selectivity determinant. In cancer cells, overexpressed p53 sequesters HDM-2, causing a fraction to traffick to the outer membrane. Normal cells do not display surface HDM-2 and are not targeted. Blocking surface HDM-2 with antibody abolishes PNC-27 cytotoxicity.
What is the Phase 0 human data?
Bowne et al. 2017 incubated PNC-27 with ascites fluid from pancreatic cancer patients and demonstrated selective lysis of tumour cells while normal cells in the same fluid survived — the first human-relevant evidence for cancer-selective membranolytic activity.
What formats does QSC supply PNC-27 in?
QSC supplies PNC-27 as lyophilised research vials (5mg per vial, 10-vial kits = 50mg total), ≥99% purity HPLC verified with Janoshik COA. Ships from domestic QSC warehouses in USA, EU, UK, Canada, and Australia.
Research Use Only: All QSC compounds are sold strictly for laboratory research purposes. Not for human use. Not approved by the FDA or equivalent regulatory bodies for human administration. All purchases confirm research intent and compliance with applicable local regulations.
